Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Simulations Plus ( (SLP) ) just unveiled an update.
On April 9, 2026, Simulations Plus reported second‑quarter fiscal 2026 results for the period ended February 28, 2026, with total revenue up 8% year on year to $24.3 million and broad-based growth in both software and services. Software sales rose 9% to $14.6 million, services revenue increased 8% to $9.7 million, and higher gross margin helped lift net income to $4.5 million, or $0.22 per diluted share, while adjusted EBITDA expanded to $8.7 million.
For the first six months of fiscal 2026, revenue grew 3% to $42.7 million, as services climbed 12% and offset a 3% decline in software, and profitability improved with gross margin rising to 63% and net income advancing to $5.2 million, or $0.26 per diluted share. Management highlighted strong bookings, an approximately 18% increase in services backlog, favorable market conditions, and steady client demand, but cut full‑year adjusted EPS guidance to $0.75–$0.85 due to a higher expected tax rate while leaving revenue, mix, and margin targets unchanged.
The most recent analyst rating on (SLP) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on Simulations Plus stock, see the SLP Stock Forecast page.
Spark’s Take on SLP Stock
According to Spark, TipRanks’ AI Analyst, SLP is a Neutral.
The score is held down primarily by the sharp TTM income-statement deterioration and very weak technical trend (price below all key moving averages with negative momentum). Offsetting these are strong balance-sheet flexibility and positive free cash flow, plus earnings-call guidance that supports stable-to-modest growth with solid adjusted profitability, though near-term demand and renewals remain pressured.
To see Spark’s full report on SLP stock, click here.
More about Simulations Plus
Simulations Plus, Inc. is a global provider of model‑informed and AI‑accelerated drug development solutions for the biopharmaceutical sector. The company creates value for clients by offering science‑based software and consulting services that support the discovery, development, and commercialization of pharmaceuticals and other regulated products.
Headquartered in Research Triangle Park, N.C., Simulations Plus focuses on software and services that help biopharma customers optimize R&D productivity and regulatory outcomes. Its revenue mix is split between subscription software tools and specialized consulting projects, positioning the firm as a key enabler of data‑driven drug development.
Average Trading Volume: 304,427
Technical Sentiment Signal: Sell
Current Market Cap: $261.9M
See more data about SLP stock on TipRanks’ Stock Analysis page.